Since the advent of anti-vascular endothelium growth factor (anti-VEGF) monoclonal antibodies, intravitreal injection of anti-VEGF therapy has proliferated from initial neovascular age-related macular degeneration (nARMD)1 to more retinal diseases such as diabetic macular edema (DME)2 and retinal vein occlusion (RVO)3. The gene discussed is VEGFA; the disease is diabetic macular edema.